{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:15Z","timestamp":1740144195634,"version":"3.37.3"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the Education Department of Jilin Province","award":["JJKH20180208KJ"],"award-info":[{"award-number":["JJKH20180208KJ"]}]},{"name":"the Health Foundation of Jilin Province","award":["No.2018J065"],"award-info":[{"award-number":["No.2018J065"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>This study was to investigate clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia (CML-DPMNs). Clinical data of thirteen CML-DPMN patients who were admitted to the First Hospital of Jilin University from May 2008 to December 2018 were collected and retrospectively analyzed. Female patients (9\/13) were predominant in this cohort study. Nine patients were metachronous DPMNs (metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia) with 5 years median interval time from primary malignancy to secondary malignancy. The other 4 patients were diagnosed as synchronous CML-DPMNs. Seven of the metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia suffered from CML following many years of comprehensive anti-cancer therapy. Two of CML-MDPMN patients had invasive ductal carcinoma of breast after many years of treatment with imatinib. There was no difference between treatment-related CML group and non-treatment-related CML group in regard as the gender, age, white blood cell count, hemoglobin level, platelet count, and risk level. The median overall survival time of these thirteen patients with CML-DPMNs was not reached. In conclusion, female patients are more likely to suffer from the CML-DPMNs in the present article. Overall survival time of patients with DPMNs involving CML could be promising if timely and effective treatment therapy is adopted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022904","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T19:01:53Z","timestamp":1603911713000},"page":"e22904","source":"Crossref","is-referenced-by-count":2,"title":["Clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia"],"prefix":"10.1097","volume":"99","author":[{"given":"Chunshui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University, Changchun"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University, Changchun"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University, Changchun"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-094X","authenticated-orcid":false,"given":"Zhihe","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"9271","DOI":"10.4238\/2014.March.12.19","article-title":"Clinical retrospective analysis of cases with multiple primary malignant neoplasms","volume":"13","author":"Xu","year":"2014","journal-title":"Genet Mol Res"},{"key":"R2-20230916","first-page":"908","article-title":"Die allgemeine chirurgische pathologie and therapie","author":"Billroth","year":"1889","journal-title":"In: 51 Vorlesungen-Ein Handbuch fur Studierende and Artze, 14"},{"key":"R3-20230916","first-page":"1358","article-title":"Multiple primary malignant tumors: a survey of the literature and a statistical study","volume":"16","author":"Warren","year":"1932","journal-title":"Am J Cancer"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00000421-200302000-00015","article-title":"Multiple primary malignant neoplasms: case report and a comprehensive review of the literature","volume":"26","author":"Demandante","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R5-20230916","first-page":"113","article-title":"The clinical pathology analysis of 172 cases of multiple primary malignant tumors","volume":"1","author":"Liu","year":"1979","journal-title":"Zhong hua Zhong Liu Za Zhi"},{"key":"R6-20230916","first-page":"296","article-title":"Double cancers: a clinical analysis of 156 cases","volume":"18","author":"Li","year":"1996","journal-title":"Zhong hua Zhong Liu Za Zhi"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.7150\/jca.25482","article-title":"Multiple primary malignant tumors - a clinical analysis of 15,321 patients with malignancies at a single center in China","volume":"9","author":"Zhai","year":"2018","journal-title":"J Cancer"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"e0125754","DOI":"10.1371\/journal.pone.0125754","article-title":"Clinical analysis of 152 cases of multiple primary malignant tumors in 15,398 patients with malignant tumors","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"e4342","DOI":"10.7717\/peerj.4342","article-title":"An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States","volume":"6","author":"Kumar","year":"2018","journal-title":"PeerJ"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3109\/10428194.2012.668684","article-title":"Chronic myeloid leukemia and risk of second malignancy in two eras of treatment","volume":"53","author":"Stein","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.clml.2016.06.010","article-title":"Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors","volume":"16","author":"Yin","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/jech.2007.063560","article-title":"New malignancies among cancer survivors: SEER cancer registries, 1973-2000","volume":"62","author":"Supramaniam","year":"2008","journal-title":"J Epidemiol Community Health"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2019good-risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"e2015003","DOI":"10.4084\/mjhid.2015.003","article-title":"Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience","volume":"7","author":"Helbig","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study","volume":"12","author":"Villani","year":"2011","journal-title":"Lancet Oncol"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.seminoncol.2003.12.035","article-title":"Multiple primary malignancies","volume":"31","author":"Luciani","year":"2004","journal-title":"Semin Oncol"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.13346","article-title":"Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era","volume":"169","author":"Gunnarsson","year":"2015","journal-title":"Br J Haematol"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.leu.2404025","article-title":"Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib","volume":"20","author":"Pilot","year":"2006","journal-title":"Leukemia"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4149\/neo_2011_03_256","article-title":"Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia","volume":"58","year":"2011","journal-title":"Neoplasma"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Alice","year":"2015","journal-title":"Ann Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:56:22Z","timestamp":1694829382000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":27,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022904","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}